Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Licenses Global Rights to Kyoto iPS Cell Patents

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has licensed worldwide rights to Kyoto University's induced pluripotent stem cell patent portfolio.

Under terms of the deal, iPS Academia Japan, which managed the patents and technology arising from Shinya Yamanaka's research at Kyoto University, will receive a license fee from Sigma-Aldrich. Financial and other terms of the license were not disclosed.

"Our license with Kyoto University grants us the freedom to operate under Kyoto University's induced pluripotent stem cell patent portfolio in the increasingly important field of stem-cell based research and development," David Smoller, chief scientific officer of Sigma-Aldrich, said in a statement. "Using the Kyoto iPS cell technology and our zinc finger protein technologies, we hope to generate stable, defined sets of cells and subsequently derived tissues whose predictive power will allow us to develop a new paradigm in assay development."

Cellular Dynamics also holds a non-exclusive license to the Kyoto iPS cell patents.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.